A clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib),shows significant affinity toward the DYRK1A and GSK3β kinases,involved in down syndrome phenotypes, Alzheimer’s disease,circadian clock regulation, and diabetes. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.